<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81830">
  <stage>Registered</stage>
  <submitdate>29/01/2007</submitdate>
  <approvaldate>29/01/2007</approvaldate>
  <actrnumber>ACTRN12607000094471</actrnumber>
  <trial_identification>
    <studytitle>Randomised control trial of monoamine precursors for the treatment of psychostimulant withdrawal</studytitle>
    <scientifictitle>A double-blind, randomised, placebo controlled trial of monoamine precursors in the treatment of psychostimulant withdrawal in adult humans seeking treatment for psychostimulant use</scientifictitle>
    <utrn />
    <trialacronym>Monoamine precursor trial</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Psychostimulant withdrawal</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral monoamine precursors (5-HTP (300mg daily), L-tyrosine (1500mg daily), dl-phenylalanine (2000mg daily)) and oral multivitamins (3 tablets daily, one multivitamin tablet is on average in the range of 1200mg  1400mg).  All participants will be offered 4 weekly sessions of outpatient cognitive behavioural therapy (CBT) of approximately one hour duration each.</interventions>
    <comparator>Oral placebo and oral multivitamins (3 tablets daily), daily for 4 weeks.  Placebos contain non-therapeutic excipients and are matched for colour and size.  All participants will be offered 4 weekly sessions of outpatient cognitive behavioural therapy (CBT) of approximately one hour duration each.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Psychostimulant withdrawal.</outcome>
      <timepoint>Self-report assessed daily for one month with the Amphetamine Cessation Symptom Assessment (ACSA).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Number of outpatient CBT sessions attended</outcome>
      <timepoint>assessed at the completion of the intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Abstinence rates, assessed using the Timeline Followback Method.</outcome>
      <timepoint>during treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria 1. DSM-IV Classification of Amphetamine or Cocaine Dependence / Severity of Dependence Scale (SDS) score greater than 4. 2. Psychostimulant use at least 2 times per week with at least 3 month history. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria 1.Alcohol dependence (AUDIT) 2. Use of drugs other than psychostimulants 4 times a week or more (nicotine dependence is permitted)3. Amino acid contraindications (eg., phenylketonuria) 4. Malabsorption medical conditions (eg., Crohns disease, ulcerative colitis) 5. Currently prescribed antidepressant / mood stabilising / antipsychotic medications 6. Current suicidal ideation 7. History of schizophrenia / other psychotic illness 8. Hospitalisation in the past 12 months for more than 24 hours for psychiatric symptoms including hallucinations, delusions and suicidal ideation 9. Elevated Liver Function Tests (3 times higher than normal levels) 10. Currently pregnant or likely to become pregnant in the following month.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation involves contacting the holder of the allocation schedule who is at central administration</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Study is double-blind. Study participants, assessing counsellor, counsellor delivering CBT intervention, and all other project staff excluding staff member responsible for randomisation will be blinded to the study condition of participants.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>31/01/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney South West Area Health Service</primarysponsorname>
    <primarysponsoraddress>Drug Health Services, Royal Prince Alfred Hospital, Missenden Rd Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NSW Department of Health</fundingname>
      <fundingaddress>73 Miller St, North Sydney, 2060</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aims to: identify the safety and acceptability of monoamine precursor provision in the management of psychostimulant withdrawal; explore the impact of monoamine precursor provision on engagement and retention in treatment; research the effect of monoamine precursor provision on the clinical course and severity of psychostimulant withdrawal; and, explore the impact of monoamine precursor provision in improving abstinence rates.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2005/112</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Adam Winstock</name>
      <address>Drug Health Services
Locked Bag 4002
Ashfield NSW 2131</address>
      <phone>+61 2 93781316</phone>
      <fax>+61 2 93781338</fax>
      <email>adam.winstock@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Toby Lea</name>
      <address>Drug Health Services
Locked Bag 4002
Ashfield NSW 2131</address>
      <phone>+61 2 93781314</phone>
      <fax>+61 2 93781338</fax>
      <email>toby.lea@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>